Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 92

1.

Tailoring CD19xCD3-DART exposure enhances T-cells to eradication of B-cell neoplasms.

Circosta P, Elia AR, Landra I, Machiorlatti R, Todaro M, Aliberti S, Brusa D, Deaglio S, Chiaretti S, Bruna R, Gottardi D, Massaia M, Giacomo FD, Guarini AR, Foà R, Kyriakides PW, Bareja R, Elemento O, Chichili GR, Monteleone E, Moore PA, Johnson S, Bonvini E, Cignetti A, Inghirami G.

Oncoimmunology. 2018 Feb 8;7(4):e1341032. doi: 10.1080/2162402X.2017.1341032. eCollection 2018.

2.

Application of dual affinity retargeting molecules to achieve optimal redirected T-cell killing of B-cell lymphoma.

Moore PA, Zhang W, Rainey GJ, Burke S, Li H, Huang L, Gorlatov S, Veri MC, Aggarwal S, Yang Y, Shah K, Jin L, Zhang S, He L, Zhang T, Ciccarone V, Koenig S, Bonvini E, Johnson S.

Blood. 2011 Apr 28;117(17):4542-51. doi: 10.1182/blood-2010-09-306449. Epub 2011 Feb 7.

3.

CD19xCD3 DART protein mediates human B-cell depletion in vivo in humanized BLT mice.

Tsai P, Thayer WO, Liu L, Silvestri G, Nordstrom JL, Garcia JV.

Mol Ther Oncolytics. 2016 Mar 2;3:15024. doi: 10.1038/mto.2015.24. eCollection 2016.

4.

Targeting of natural killer-like T immunologic effector cells against leukemia and lymphoma cells by reverse antibody-dependent cellular cytotoxicity.

Lefterova P, Märten A, Buttgereit P, Weineck S, Scheffold C, Huhn D, Schmidt-Wolf IG.

J Immunother. 2000 May-Jun;23(3):304-10.

PMID:
10838659
5.

A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells.

Reusch U, Duell J, Ellwanger K, Herbrecht C, Knackmuss SH, Fucek I, Eser M, McAleese F, Molkenthin V, Gall FL, Topp M, Little M, Zhukovsky EA.

MAbs. 2015;7(3):584-604. doi: 10.1080/19420862.2015.1029216.

6.
7.

Enhanced killing of primary ovarian cancer by retargeting autologous cytokine-induced killer cells with bispecific antibodies: a preclinical study.

Chan JK, Hamilton CA, Cheung MK, Karimi M, Baker J, Gall JM, Schulz S, Thorne SH, Teng NN, Contag CH, Lum LG, Negrin RS.

Clin Cancer Res. 2006 Mar 15;12(6):1859-67.

8.

Chimeric antigen receptor-engineered cytokine-induced killer cells overcome treatment resistance of pre-B-cell acute lymphoblastic leukemia and enhance survival.

Oelsner S, Wagner J, Friede ME, Pfirrmann V, Genßler S, Rettinger E, Buchholz CJ, Pfeifer H, Schubert R, Ottmann OG, Ullrich E, Bader P, Wels WS.

Int J Cancer. 2016 Oct 15;139(8):1799-809. doi: 10.1002/ijc.30217. Epub 2016 Jun 11.

9.

Redirection of CD4+ and CD8+ T lymphocytes via an anti-CD3 × anti-CD19 bi-specific antibody combined with cytosine arabinoside and the efficient lysis of patient-derived B-ALL cells.

Fan D, Li W, Yang Y, Zhang X, Zhang Q, Yan Y, Yang M, Wang J, Xiong D.

J Hematol Oncol. 2015 Oct 6;8:108. doi: 10.1186/s13045-015-0205-6.

10.

Serial killing of tumor cells by cytotoxic T cells redirected with a CD19-/CD3-bispecific single-chain antibody construct.

Hoffmann P, Hofmeister R, Brischwein K, Brandl C, Crommer S, Bargou R, Itin C, Prang N, Baeuerle PA.

Int J Cancer. 2005 May 20;115(1):98-104.

11.

Cytokine-induced killer cells targeted by the novel bispecific antibody CD19xCD5 (HD37xT5.16) efficiently lyse B-lymphoma cells.

Tita-Nwa F, Moldenhauer G, Herbst M, Kleist C, Ho AD, Kornacker M.

Cancer Immunol Immunother. 2007 Dec;56(12):1911-20. Epub 2007 May 9.

PMID:
17487487
12.

A recombinant bispecific single-chain antibody, CD19 x CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes.

Löffler A, Kufer P, Lutterbüse R, Zettl F, Daniel PT, Schwenkenbecher JM, Riethmüller G, Dörken B, Bargou RC.

Blood. 2000 Mar 15;95(6):2098-103.

13.

Targeting CD123 in acute myeloid leukemia using a T-cell-directed dual-affinity retargeting platform.

Al-Hussaini M, Rettig MP, Ritchey JK, Karpova D, Uy GL, Eissenberg LG, Gao F, Eades WC, Bonvini E, Chichili GR, Moore PA, Johnson S, Collins L, DiPersio JF.

Blood. 2016 Jan 7;127(1):122-31. doi: 10.1182/blood-2014-05-575704. Epub 2015 Nov 3.

14.

Effector cell recruitment with novel Fv-based dual-affinity re-targeting protein leads to potent tumor cytolysis and in vivo B-cell depletion.

Johnson S, Burke S, Huang L, Gorlatov S, Li H, Wang W, Zhang W, Tuaillon N, Rainey J, Barat B, Yang Y, Jin L, Ciccarone V, Moore PA, Koenig S, Bonvini E.

J Mol Biol. 2010 Jun 11;399(3):436-49. doi: 10.1016/j.jmb.2010.04.001. Epub 2010 Apr 9.

PMID:
20382161
16.

Visualization of effective tumor targeting by CD8+ natural killer T cells redirected with bispecific antibody F(ab')(2)HER2xCD3.

Scheffold C, Kornacker M, Scheffold YC, Contag CH, Negrin RS.

Cancer Res. 2002 Oct 15;62(20):5785-91.

17.

Extremely potent, rapid and costimulation-independent cytotoxic T-cell response against lymphoma cells catalyzed by a single-chain bispecific antibody.

Dreier T, Lorenczewski G, Brandl C, Hoffmann P, Syring U, Hanakam F, Kufer P, Riethmuller G, Bargou R, Baeuerle PA.

Int J Cancer. 2002 Aug 20;100(6):690-7.

18.

T-cell responses against CD19+ pediatric acute lymphoblastic leukemia mediated by bispecific T-cell engager (BiTE) are regulated contrarily by PD-L1 and CD80/CD86 on leukemic blasts.

Feucht J, Kayser S, Gorodezki D, Hamieh M, Döring M, Blaeschke F, Schlegel P, Bösmüller H, Quintanilla-Fend L, Ebinger M, Lang P, Handgretinger R, Feuchtinger T.

Oncotarget. 2016 Nov 22;7(47):76902-76919. doi: 10.18632/oncotarget.12357.

19.

Cytolysis of leukemic B-cells by T-cells activated via two bispecific antibodies.

Bohlen H, Manzke O, Patel B, Moldenhauer G, Dörken B, von Fliedner V, Diehl V, Tesch H.

Cancer Res. 1993 Sep 15;53(18):4310-4.

20.

Mesenchymal stromal cells as vehicles of tetravalent bispecific Tandab (CD3/CD19) for the treatment of B cell lymphoma combined with IDO pathway inhibitor D-1-methyl-tryptophan.

Zhang X, Yang Y, Zhang L, Lu Y, Zhang Q, Fan D, Zhang Y, Zhang Y, Ye Z, Xiong D.

J Hematol Oncol. 2017 Feb 23;10(1):56. doi: 10.1186/s13045-017-0397-z.

Supplemental Content

Support Center